GenVec — Shareholder Meeting (June 2006)
24 slides from GenVec's shareholder meeting presentation, Jun 22, 2006
Slide 1: GenVec, Inc. Annual Shareholders Meeting
GenVec, Inc. Annual Shareholders Meeting June 22, 2006 Non-confidential
Slide 2: Forward-Looking Statements
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward- looking statements within the meaning of the Private Securities Litigation
Slide 3: GenVec Today
GenVec Today TNFerade - Late stage oncology product candidate Efficient drug delivery technology enables broad therapeutic and vaccine pipeline Multiple, fully-funded vaccine programs
Slide 4: Our Platform Technology
Our Platform Technology We use adenovectors to deliver genes to cells: Stimulate local production of target protein Permit sustained protein levels at disease site, increased efficacy, reduced side effects Applicable to therapeutics and vaccines Acceptable to regulatory agencies Well-characterized b
Slide 5: TNFerade: A Better Way to Deliver TNFα to Treat Cancer
TNFerade: A Better Way to Deliver TNF? to Treat Cancer TNF? is well characterized anti-tumor cytokine, approved in Europe to treat soft tissue sarcoma (Beromun(tm)) Side effects resulting from systemic administration of TNF? protein have limited its clinical use to local perfusion strategies TNFerad
Slide 6: TNFerade: A New Treatment Paradigm
TNFerade: A New Treatment Paradigm Maximize anti-tumor activity of TNF? Use in combination with front-line therapy - chemotherapy and/or radiation Direct injection into the tumor Clinical objectives: Prolong patient survival Increase tumor shrinkage Improve surgical outcomes
Slide 7: TNFerade: Significant Clinical Data
TNFerade: Significant Clinical Data Over 150 Patients in Phase I and Phase II Trials Proof of Concept in Soft Tissue Sarcoma Activity across a broad range of tumors Ongoing Phase II/III trial in locally advanced pancreatic cancer targeting 330 patients Phase II data in esophageal and pancreatic Ongo
Slide 8: GI Cancers - Large Unmet Medical Need
GI Cancers - Large Unmet Medical Need Source: American Cancer Society - Cancer Facts & Figures 2005 (U.S. Market Only) Esophageal Cancer 14,500 new cases/year Pancreatic Cancer 32,000 new cases/year Rectal Cancer 40,000 new cases/year
Slide 9: TNFerade Improve Front-line Therapy
TNFerade Improve Front-line Therapy Combine with Standard of Care (chemoradiation) Enhance surgical resection of tumor Slow disease progression Improve survival Well tolerated, no added toxicities
Slide 10: TNFerade for Pancreatic Cancer Phase II Dose Escalation Study in 50 Patients
Patient Population: Locally advanced, unresectable adenocarcinoma of the pancreas Study Treatment: TNFerade(tm) delivered in 5 weekly intratumoral injections at four escalating dose levels (4x109, 4x1010, 4x1011, and 1x1012 pu) PTA delivery EUS delivery Concurrent chemoradiation: 50.4 Gy radiation p
Slide 11: Patients Whose Tumors Shrank >25%
Patients Whose Tumors Shrank >25% Standard of Care (average of ten recent studies) Standard of Care plus TNFerade(tm) (4x1011 pu) (ASCO May 2005) 60% 15% 60% 50% 40% 30% 20% 10% 0% TNFerade(tm) Phase II Results Pancreatic Cancer Dose Escalation Trial
Slide 12: Patients Whose Tumors Were Resected
TNFerade(tm) Phase II Results Pancreatic Cancer Dose Escalation Trial Patients Whose Tumors Were Resected Standard of Care (average of ten recent studies) Standard of Care plus TNFerade(tm) (4x1011 pu) (ASCO May 2005) 45% 5% 60% 50% 40% 30% 20% 10% 0%
Slide 13: Patients Surviving > 24 Months
TNFerade(tm) Phase II Results Pancreatic Cancer Dose Escalation Trial Patients Surviving > 24 Months Standard of Care (DeVita et al., 6th Ed.) Standard of Care plus TNFerade(tm) (4x1011 pu) (13th Annual Conf. on Gene Therapy of Cancer) 34% 12% 50% 40% 30% 20% 10% 0%
Slide 14: TNFerade is now a Phase III Program
TNFerade(tm) is now a Phase III Program Pivotal Trial with target of 330 patients Amended Phase II Pancreatic Protocol 2:1 randomization Front line therapy in combination with chemoradiation Maintenance therapy with Gemzar and Tarceva Endpoint of survival at 12 months vs. SOC 12 month overall surviv
Slide 15: Clinical Development Challenges
Clinical Development Challenges Competition for patients Large number of competing trials Increasing number of US and Ex-US sites Engaging CROs to enhance clinical development efforts New treatment paradigm in treating pancreatic cancer Presentations to scientific and medical communities Increasing
Slide 16: TNFerade Betters Outcome of Historical Esophageal Trials
TNFerade Betters Outcome of Historical Esophageal Trials ( Previous RCTs of Neoadjuvant CRT) All TNFerade(tm) Dose Cohorts (Pooled) Median: Not yet achieved 12-month rate: 88% 18-month rate: 83% 24-month rate: 64% 36-month rate: 64% 0.00 0.25 0.50 0.75 1.00 0 6 12 18 24 30 36 Survival Months since s
Slide 17: TNFerade Clinical Pipeline
TNFerade Clinical Pipeline TNFerade(tm) For Cancer Phase I Phase II Phase III Completed Studies: Solid Tumors (13 different cancers) Soft Tissue Sarcomas Esophageal Cancer (Non-Metastatic) Pancreatic Cancer (Locally Advanced) Ongoing Studies: Pancreatic Cancer (Locally Advanced) Rectal Cancer (NCI s
Slide 18: Broader GI Cancer Opportunity
Broader GI Cancer Opportunity 100,000 new GI cancer patients annually in US 300,000 new patients annually in 7 major markets WW Pancreatic, esophageal and rectal cancer Significant unmet need exists Leverages same physician target - GI Head & Neck cancer incremental Melanoma incremental
Slide 19: Additional Pipeline Programs
Additional Pipeline Programs AdPEDF for vision loss (wet AMD) Phase I enrollment completed Positive results to date ATOH for hearing loss Gene delivery restores hair cells and function in hearing/balance models
Slide 20: Broad Flexible Technology Platform
Broad Flexible Technology Platform GMP Manufacturing QA/QC Infrastructure Assay Development 293-ORF6 Cell Line Next Generation Vectors Strong IP Portfolio Core Technology Platform Vaccines HIV Global Vaccine Influenza Malaria Foot & Mouth Disease Therapeutics TNFerade AdPEDF Hearing Loss Improving R
Slide 21: Vaccine Programs
Vaccine Programs $20 million in annual revenue 10,000 patient Phase II HIV study planned Flu research program recently expanded by NIH Malaria vaccine Phase I study with U.S. Navy Animal vaccine against foot and mouth disease in collaboration with US Dept of Agriculture
Slide 22: Financial Summary
Financial Summary Cash Balance at 3/31/06 $27M Committed Equity Facility Kingsbridge Capital Up to $30M Shares Outstanding 64M 2006 Outlook Revenues $20M+ Net Loss $18 to $20M
Slide 23: The Year Ahead
The Year Ahead Data from Phase II portion of ongoing randomized pancreatic cancer study for presentation in 1st half of 2007 Data from rectal and melanoma studies anticipated in 2007 Data from completed 22 patient AMD study with AdPEDF anticipated in 2nd half - 2006 Data from Phase I and Phase II HI
Slide 24: GNVC www.genvec.com
www.genvec.com GNVC @ Genvec